RxDoctor Payments Data

Nicole Lytle, PA

Physician Assistant · Athens, GANPI 1174654651

Payments from drug & device makers

$1,674in general payments, 2019–2025

Across 81 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$318
  • Neurocrine Biosciences, Inc.$302
  • Indivior Inc.$253
  • Johnson & Johnson$214
  • Alkermes, Inc.$146
  • Vanda Pharmaceuticals Inc.$111
  • plus $329 from 6 others

What the payments were for

  • Food & beverage$1,674100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,674 in reported general payments places this provider in the 75th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$11,461
Medicare patients
68
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate41$100,982
VraylarCariprazine Hcl32$47,116
Lurasidone Hcl18$8,832
Duloxetine Hcl122$7,387
VyvanseLisdexamfetamine Dimesylate11$4,366
Aripiprazole101$3,790
Buspirone Hcl175$3,049
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl53$2,624
Oxcarbazepine61$2,592
Clozapine24$2,438
Hydroxyzine Pamoate146$2,413
Olanzapine124$2,055
Quetiapine Fumarate107$1,474
Ziprasidone Hcl33$1,448
Divalproex Sodium27$1,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$214$100,98241 claims
AbbVieVraylar$98$47,11632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →